Tech Company Financing Transactions
Biofidelity Funding Round
Biofidelity closed a $24 million financing round on 4/3/2024. Backers included Agilent Technologies, BlueYard Capital and Longwall Venture Partners.
Transaction Overview
Company Name
Announced On
4/3/2024
Transaction Type
Venture Equity
Amount
$24,000,000
Round
Undisclosed
Proceeds Purpose
The company intends to use the funds to accelerate growth, including commercial and clinical expansion in the United States to accelerate the adoption of ASPYRE®-Lung, a novel test that simplifies and accelerates the detection of biomarkers for non-small cell lung cancer (NSCLC), enabling clinicians to determine which treatment is best for each patient in days instead of weeks and at a fraction of the cost of current sequencing tests.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
5151 McCrimmon Parkway 230
Morrisville, NC 27560
USA
Morrisville, NC 27560
USA
Phone
Website
Email Address
Not Recorded
Overview
Our mission is to transform human health and the world we live in by developing innovative technologies that unleash the potential of genomics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Heiner Dreismann
Chief Executive Officer
Barnaby Balmforth
Chief Medical Officer
Wendy Levin
Chief Operating Officer
Robert Osborne
VP - Bus. Development
Stephen Miller
Browse more venture capital transactions:
Prev: 4/2/2024: Delivery Collective venture capital transaction
Next: 4/3/2024: Constantinople venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs